Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
Arthritis Rheumatol
.
2021 Sep;73(9):1768-1769.
doi: 10.1002/art.41806.
Epub 2021 Jul 29.
Authors
Mahta Mortezavi
1
,
Sujatha Menon
1
,
Kristen Lee
2
,
Jose Rivas
3
Affiliations
1
Pfizer Inc, New York, NY.
2
Pfizer Inc, Groton, CT.
3
Pfizer SLU, Madrid, Spain.
PMID:
34042319
PMCID:
PMC8239861
DOI:
10.1002/art.41806
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19 Vaccines
COVID-19*
Humans
Piperidines
Pyrimidines
Rheumatic Diseases* / drug therapy
Rheumatology*
SARS-CoV-2
United States
Vaccination
Substances
COVID-19 Vaccines
Piperidines
Pyrimidines
tofacitinib
Grants and funding
Pfizer Inc